Antares Pharma Inc. ATRS was a big mover last session, as the company saw its shares rise more than 10% on the day. Shares moved up after the company along with Teva Pharmaceutical Industries Ltd announced the launch of the generic …
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly ... https://investorplace.com/2014/06/4-medical-devices-stocks-to-buy-now-wwin-atrs-nvcn/.
and they also are very bullish on a mega-cap technology stock and a small-cap biotech. All are rated Buy at Jefferies. This small-cap biotech may prove to be a big-time winner for aggressive accounts. Antares Pharma Inc. (NASDAQ: ATRS) …
In after-hours, the stock was up 45.36% to $37.30 ... The FDA has declined to approve Antares Pharma Inc.'s (ATRS) Xyosted, a drug-device combination product, for the treatment of adult men with low testosterone associated with a …
ticker=INFI (NASDAQ: INFI) Antares Pharma Inc.'s (NASDAQ: ATRS) stock moved 5.33% lower Thursday, to close the day at $3.73. The stock recorded a trading volume of 6,280,425 shares, which was above its three months average …
Each of these rates an “A” (“strong buy”) or “B” overall (“buy”). Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures.
A year ago, they were trading at $2.99. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ATRS at https://www.zacks.com/ap/ATRS